FDA Approved: IMATINIB MESYLATE — Supplemental Application (BluePoint Laboratories)

View source ↗

Summary

FDA approves a supplemental application for Imatinib Mesylate from BluePoint Laboratories under an ANDA, confirming approval of a generic product. The drug is i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Myeloid Leukemia
• Dermatofibrosarcoma Protuberans
• Gastrointestinal Stromal Tumor

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

SUPPL AP for IMATINIB MESYLATE (IMATINIB MESYLATE)